Faraday Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2014-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.faradaypharma.com
Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Evaluation in STEMI Patients Using FDY-5301
- Conditions
- STEMIPercutaneous Coronary RevascularizationAcute Myocardial Infarction
- Interventions
- Other: Placebo
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Faraday Pharmaceuticals, Inc.
- Target Recruit Count
- 2351
- Registration Number
- NCT04837001
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Florida Health, Jacksonville, Florida, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Evaluation of FDY-5301 in Major Trauma Patients in ICU
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Faraday Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04430283
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Florida Health Shands Hospital, Gainesville, Florida, United States
🇺🇸Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
A Study of Acute Myocardial Infarction Using FDY-5301
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Faraday Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03470441
- Locations
- 🇺🇸
Minneapolis Heart Institute, Minneapolis, Minnesota, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
🇭🇺Budai Irgalmasrendi Kórház, Budapest, Hungary